The French pharmaceutical giant Sanofi would consider removing 400 positions devoted to pharmaceutical research, reports France Inter, relaying information transmitted by the CGT.
With other organizations in the group, this union calls a strike on Tuesday.
“
400 jobs will be eliminated in France
”, in R&D according to Thierry Bodin of the CGT, quoted by public radio.
In reality, these job cuts are not new.
The laboratory announced last June its intention to cut 1,700 jobs in Europe over three years, including 1,000 jobs in France (out of 25,000 employees).
"
It is only about early retirement and voluntary departures
", had indicated the management.
Among the positions targeted: tertiary and support functions, as well as R&D.
Contacted by Le Figaro, the management did not wish to confirm this number.
"
In accordance with our obligations and the social dialogue within the company, we do not communicate information before presenting it to the employee representative bodies
".
Read also: New slimming diet at Sanofi
The June announcement had the effect of a bomb in the midst of the Covid epidemic, and ten days after Emmanuel Macron's visit to a Sanofi vaccine production plant.
Unlike many social plans, these decisions are not related to Covid-19.
They were taken before the health crisis.
The roadmap of Sanofi CEO Paul Hudson, who is committed to relaunching Sanofi, indeed involves
revitalizing R&D: the French laboratory wants to renew its portfolio of molecules to prepare for the future.
